dr. davids on ibrutinib plus fcr in younger patients with cll
Published 6 years ago • 126 plays • Length 1:17Download video MP4
Download video MP3
Similar videos
-
0:53
dr. davids discusses duvelisib plus fcr in young patients with cll
-
2:01
exciting results for frontline ibrutinib plus fcr for younger cll patients
-
1:09
dr. davids discusses the results of ibrutinib plus fcr in cll
-
0:49
matthew davids, md discusses his study using ibrutinib plus fcr in younger cll patients
-
2:26
a phase ii study of ibrutinib plus fcr as frontline therapy in younger cll patients
-
1:44
ibrutinib and fcr in cll irrespective of ighv mutation status
-
0:47
dr. davids on remaining questions with umbralisib/ibrutinib in cll and mcl
-
9:03
up-front ibrutinib versus fcr for patients with cll
-
1:22
dr. davids on updated data with ibrutinib/umbralisib in r/r cll and mcl
-
1:28
frontline ibrutinib-fcr for younger cll patients: phase ii results
-
7:01
novel frontline combinations with ibrutinib in cll
-
2:34
dr. davids on the combination of ibrutinib and obinutuzumab in cll
-
1:09
dr. davids on results of obinutuzumab with ibrutinib
-
1:33
dr. zelenetz on treatment for patients with cll who fail on ibrutinib or idelalisib
-
1:14
dr. davids on exciting data with acalabrutinib in cll
-
1:07
dr. davids on the potential utility of ibrutinib/umbralisib in mcl and cll
-
0:59
dr. davids on frontline challenges in cll
-
3:33
dr. matthew davids on advances in cll treatment | dana-farber cancer institute
-
1:16
preliminary results of ibruntinib in combination with fcr chemotherapy for cll